Form 4: Immunovant's Chief Legal Officer Sells Shares to Cover Tax Obligations

Mark S. Levine, Chief Legal Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 17, 2024, Mark S. Levine, the Chief Legal Officer of Immunovant, Inc., sold 2,358 shares of common stock at a weighted average price of $29.64.
• He also sold 147 shares of common stock at a weighted average price of $30.55.
• These sales were to cover tax withholding obligations related to the vesting of 5,479 restricted stock units (RSUs) on July 12, 2024.
• The sales were mandated by Immunovant's policy requiring tax obligations to be funded by a 'sell to cover' transaction.
• Following these transactions, Levine beneficially owns 337,409 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The Form 4 filing represents a routine transaction (sell to cover taxes) and does not inherently indicate positive or negative sentiment regarding the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.

Comparison to Industry Standards

• Similar 'sell to cover' transactions are frequently observed among executives at comparable biotech companies like Amgen, Regeneron, and Biogen when RSUs vest.
• The weighted average prices at which the shares were sold are within a typical range for such transactions, reflecting the market price of Immunovant's stock at the time.
• The number of shares sold is proportional to the tax obligations arising from the vesting of the RSUs, aligning with standard industry practice.

Key Dates